BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioAge Labs (BIOA) will participate in two investor conferences on September 29 and 30, 2026.
Company representatives will hold one-on-one meetings at the ROTH Healthcare Opportunities Conference in New York on September 29 and the Stifel Virtual Cardiometabolic Forum on September 30. Chief Strategy Officer BJ Sullivan is scheduled for a Stifel fireside chat at 1 PM EDT.
BioAge Labs (BIOA) has dosed the first participant in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral NLRP3 inhibitor BGE-102 in adults with diabetic macular edema (DME).
The approximately 180-participant study will test BGE-102 both as monotherapy and in combination with standard-of-care intravitreal anti-VEGF therapy. Participants are randomized 1:1:1 to three arms: anti-VEGF plus oral placebo, anti-VEGF plus BGE-102 90 mg once daily, or sham intravitreal injection plus BGE-102 90 mg once daily. Treatment lasts 12 weeks with a 4‑week follow-up. The primary endpoint is change from baseline in best-corrected visual acuity at week 12, with exploratory endpoints including retinal measures and intraocular and plasma biomarkers. Topline results are anticipated in the second half of 2027.
BioAge Labs (BIOA) will present at three investor conferences in New York in September 2026, featuring fireside chats and one-on-one meetings with senior management.
Events include the Citi Biopharma Back to School Conference (Sept 9–10), Cantor Global Healthcare Conference (Sept 9–11), and Morgan Stanley 24th Annual Global Healthcare Conference (Sept 14–16), with webcast access and 30-day replays available via the company’s investor website.
BioArctic (Nasdaq Stockholm: BIOA B) issued 20,200 new Class B shares in August 2026 following the exercise of 20,200 stock options from the 2019/2028 program approved on May 9, 2019. As of August 31, 2026, BioArctic had a total of 88,744,685 shares outstanding, comprising 74,344,689 listed Class B shares and 14,399,996 unlisted Class A shares. Class A shares carry ten votes per share and Class B shares one vote per share, giving a total of 218,344,649 votes in the company.
BioAge Labs (NASDAQ:BIOA) reported second quarter 2026 collaboration revenue of $2.5 million, roughly flat year over year, and a net loss of $26.1 million (basic and diluted loss per share $0.58) versus a $21.6 million loss a year earlier. Research and development expenses rose to $24.4 million, mainly from higher BGE-102 program costs, while general and administrative expenses were $7.4 million.
As of June 30, 2026, BioAge held $381.3 million in cash, cash equivalents, and marketable securities and estimates funding through 2029. The first participant was dosed in QUELL-CV, a Phase 2 proof-of-concept trial of NLRP3 inhibitor BGE-102 in obesity with inflammation, with topline data expected in 2H 2026. A Phase 1b/2a trial in diabetic macular edema, QUELL-DME, is planned to start mid-2026, with data anticipated mid-2027. BioAge also advanced its APJ agonist programs and continued discovery collaborations with Novartis and Lilly ExploR&D.
BioAge Labs (Nasdaq:BIOA) has dosed the first participant in QUELL-CV, a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial of oral NLRP3 inhibitor BGE-102 in adults at elevated cardiovascular risk.
The 12-week trial will enroll ~160 participants across four arms to evaluate three once-daily doses versus placebo, with percent change in high-sensitivity C-reactive protein (hsCRP) as the primary endpoint and topline data expected in the second half of 2026.
BioAge Labs (NASDAQ:BIOA) will participate in two upcoming investor conferences. Management will join fireside chats and one-on-one meetings at the Jefferies Global Healthcare Conference in New York on June 4, 2026, and the Goldman Sachs Global Healthcare Conference in Miami Beach on June 8, 2025.
Live webcasts will be accessible via registration links, with replays available for 30 days in the investor section of BioAge’s website.
BioAge (NASDAQ: BIOA) reported positive topline Phase 1 data for oral NLRP3 inhibitor BGE-102, showing median hsCRP reductions of 86% across 60 mg and 120 mg once-daily cohorts and 87–93% of participants reaching hsCRP <2 mg/L. BGE-102 was well tolerated. The company plans two mid-2026 proof-of-concept trials (cardiovascular risk Phase 2 and DME Phase 1b/2a) with data expected by end-2026 and mid-2027. BioAge completed an upsized follow-on offering raising $132.3M. Q1 2026: collaboration revenue $2.8M, R&D $20.4M, G&A $7.7M, net loss $22.3M ($0.52), cash $384.9M; runway through 2029.
BioAge (Nasdaq: BIOA) will host an R&D Day webcast on May 8, 2026 from 12:30–2:00 PM ET focused on BGE-102, an orally available NLRP3 inflammasome inhibitor. Management will present Phase 1 clinical data and the therapeutic rationale for ASCVD and retinal disease.
Four academic and clinical experts will join presentations and a live Q&A. A recording will be available in the company's Events section at the investor relations website.
BioAge (Nasdaq: BIOA) reported Phase 1 data for oral NLRP3 inhibitor BGE-102, showing rapid, large reductions in inflammatory biomarkers. In participants with obesity and elevated hsCRP, 60 mg QD (21 days) and 120 mg QD (14 days) produced median hsCRP reductions of ~85% and ~83–86%, respectively.
BGE-102 was well tolerated with no serious adverse events. BioAge plans a Phase 2 cardiovascular risk trial in H1 2026 with data expected H2 2026, and a Phase 1b/2a DME trial beginning mid-2026 with results anticipated mid-2027.